{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:58:24Z","timestamp":1785484704195,"version":"3.56.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":99,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004095","name":"Kyowa Kirin Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi Sankyo Chemical Pharma Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.lrr.2026.100586","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T09:15:08Z","timestamp":1775898908000},"page":"100586","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeting nucleotide metabolism and epigenetic regulation to overcome the differentiation blockade in AML"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0011-6065","authenticated-orcid":false,"given":"Shinichiro","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.lrr.2026.100586_bib0001","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17071141","article-title":"Recent developments in differentiation therapy of acute myeloid leukemia","volume":"17","author":"Testa","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.lrr.2026.100586_bib0002","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s12185-018-2534-z","article-title":"Metabolism as master of hematopoietic stem cell fate","volume":"109","author":"Ito","year":"2019","journal-title":"Int. J. Hematol."},{"issue":"6","key":"10.1016\/j.lrr.2026.100586_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102651","article-title":"Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia","volume":"24","author":"Zee","year":"2021","journal-title":"iScience"},{"issue":"24","key":"10.1016\/j.lrr.2026.100586_bib0004","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2022112348","article-title":"Bidirectional interplay between metabolism and epigenetics in hematopoietic stem cells and leukemia","volume":"42","author":"Zhang","year":"2023","journal-title":"EMBO J."},{"issue":"7","key":"10.1016\/j.lrr.2026.100586_bib0005","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202115203","article-title":"Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia","volume":"14","author":"So","year":"2022","journal-title":"EMBO. Mol. Med."},{"issue":"1","key":"10.1016\/j.lrr.2026.100586_bib0006","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1038\/s41467-025-57544-9","article-title":"Guanine nucleotide biosynthesis blockade impairs MLL complex formation and sensitizes leukemias to menin inhibition","volume":"16","author":"Shi","year":"2025","journal-title":"Nat. Commun."},{"issue":"26","key":"10.1016\/j.lrr.2026.100586_bib0007","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1182\/blood.2021015108","article-title":"Disruption of dNTP homeostasis by ribonucleotide reductase hyperactivation overcomes AML differentiation blockade","volume":"139","author":"Wang","year":"2022","journal-title":"Blood"},{"issue":"42","key":"10.1016\/j.lrr.2026.100586_bib0008","doi-asserted-by":"crossref","first-page":"15257","DOI":"10.1074\/jbc.RA119.009396","article-title":"The ribonucleoside AICAr induces differentiation of myeloid leukemia by activating the ATR\/Chk1 via pyrimidine depletion","volume":"294","author":"Dembitz","year":"2019","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.lrr.2026.100586_bib0009","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.lrr.2026.100586_bib0010","doi-asserted-by":"crossref","DOI":"10.3390\/curroncol33010025","article-title":"Reawakening differentiation therapy in acute myeloid leukemia: a comprehensive review of atra-based combination strategies","volume":"33","author":"Takahashi","year":"2026","journal-title":"Curr. Oncol."},{"issue":"25","key":"10.1016\/j.lrr.2026.100586_bib0011","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in idh1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.lrr.2026.100586_bib0012","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.lrr.2026.100586_bib0013","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1182\/blood-2012-01-402545","article-title":"Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3\/ITD AML","volume":"120","author":"Sexauer","year":"2012","journal-title":"Blood"},{"issue":"7954","key":"10.1016\/j.lrr.2026.100586_bib0014","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"issue":"1-2","key":"10.1016\/j.lrr.2026.100586_bib0015","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/10428190009053552","article-title":"Combination of granulocyte colony-stimulating factor and low-dose cytosine arabinoside further enhances myeloid differentiation in leukemia cells in vitro","volume":"39","author":"Katagiri","year":"2000","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.lrr.2026.100586_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1432-0436.2000.066001001.x","article-title":"Evidence of a functional role for the cyclin-dependent kinase inhibitor p21CIP1 in leukemic cell (U937) differentiation induced by low concentrations of 1-beta-D-arabinofuranosylcytosine","volume":"66","author":"Wang","year":"2000","journal-title":"Differentiation"},{"issue":"1","key":"10.1016\/j.lrr.2026.100586_bib0017","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-15520-z","article-title":"Cytarabine-induced differentiation of AML cells depends on Chk1 activation and shares the mechanism with inhibitors of DHODH and pyrimidine synthesis","volume":"12","author":"Tomic","year":"2022","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.lrr.2026.100586_bib0018","doi-asserted-by":"crossref","first-page":"6183","DOI":"10.3390\/ijms16036183","article-title":"DNA damage: a sensible mediator of the differentiation decision in hematopoietic stem cells and in leukemia","volume":"16","author":"Weiss","year":"2015","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.lrr.2026.100586_bib0019","first-page":"508","article-title":"Cell cycle control in acute myeloid leukemia","volume":"2","author":"Schnerch","year":"2012","journal-title":"Am. J. Cancer Res."},{"issue":"13","key":"10.1016\/j.lrr.2026.100586_bib0020","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1158\/1078-0432.CCR-16-0083","article-title":"Achieving Precision Death with Cell-Cycle Inhibitors that Target DNA Replication and Repair","volume":"23","author":"Lin","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lrr.2026.100586_bib0021","article-title":"Mutations of FLT3 receptor affect its surface glycosylation, intracellular localization, and downstream signaling","volume":"13","author":"Takahashi","year":"2020","journal-title":"Leuk Res. Rep."},{"issue":"9","key":"10.1016\/j.lrr.2026.100586_bib0022","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1158\/2159-8290.CD-15-0298","article-title":"Mass cytometric functional profiling of acute myeloid leukemia defines cell-cycle and immunophenotypic properties that correlate with known responses to therapy","volume":"5","author":"Behbehani","year":"2015","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.lrr.2026.100586_bib0023","first-page":"293","article-title":"Evidence for a relationship between intracellular GTP levels and the induction of HL-60 leukemia cell differentiation by 5,10-dideazatetrahydrofolic acid (DDATHF)","volume":"5","author":"Sokoloski","year":"1993","journal-title":"Oncol Res."},{"key":"10.1016\/j.lrr.2026.100586_bib0024","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.pharmthera.2018.10.012","article-title":"Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer","volume":"195","author":"Madak","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.lrr.2026.100586_bib0025","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1042\/CBI20100728","article-title":"Guanosine supplementation reduces the antiproliferative and apoptotic effects of the IMPDH inhibitor gnidilatimonoein in K562 cells","volume":"35","author":"Nouri","year":"2011","journal-title":"Cell Biol. Int."},{"issue":"3","key":"10.1016\/j.lrr.2026.100586_bib0026","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.taap.2011.02.021","article-title":"Intracellular GTP level determines cell's fate toward differentiation and apoptosis","volume":"253","author":"Meshkini","year":"2011","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"4","key":"10.1016\/j.lrr.2026.100586_bib0027","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.bbrc.2016.06.158","article-title":"Myricetin is a novel inhibitor of human inosine 5\u2032-monophosphate dehydrogenase with anti-leukemia activity","volume":"477","author":"Pan","year":"2016","journal-title":"Biochem. Biophys.. Res Commun."},{"issue":"28","key":"10.1016\/j.lrr.2026.100586_bib0028","doi-asserted-by":"crossref","first-page":"23635","DOI":"10.1074\/jbc.M111.312801","article-title":"ATP depletion triggers acute myeloid leukemia differentiation through an ATR\/Chk1 protein-dependent and p53 protein-independent pathway","volume":"287","author":"Chakrabarti","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.lrr.2026.100586_bib0029","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.leukres.2008.07.027","article-title":"Aberrant DNA methylation of the transcription factor C\/EBPalpha in acute myelogenous leukemia","volume":"33","author":"Jost","year":"2009","journal-title":"Leuk Res."},{"issue":"7","key":"10.1016\/j.lrr.2026.100586_bib0030","doi-asserted-by":"crossref","DOI":"10.3390\/ph14070641","article-title":"Hypomethylating chemotherapeutic agents as therapy for myelodysplastic syndromes and prevention of acute myeloid leukemia","volume":"14","author":"Sorrentino","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"10.1016\/j.lrr.2026.100586_bib0031","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/17474086.2018.1453802","article-title":"Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia","volume":"11","author":"Bohl","year":"2018","journal-title":"Expert Rev. Hematol."},{"issue":"8","key":"10.1016\/j.lrr.2026.100586_bib0032","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2012.47","article-title":"5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity","volume":"26","author":"Curik","year":"2012","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.lrr.2026.100586_bib0033","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0014-4827(03)00032-6","article-title":"5-azacytidine reactivates the erythroid differentiation potential of the myeloid-restricted murine cell line 32D Ro","volume":"285","author":"Baiocchi","year":"2003","journal-title":"Exp. Cell Res."},{"issue":"1","key":"10.1016\/j.lrr.2026.100586_bib0034","first-page":"111","article-title":"Effect of trichostatin a and 5\u2032-azacytidine on transgene reactivation in U937 transduced cells","volume":"48","author":"Bartoli","year":"2003","journal-title":"Pharmacol. Res."},{"issue":"12","key":"10.1016\/j.lrr.2026.100586_bib0035","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23126729","article-title":"Combined approach to leukemic differentiation using transcription factor PU.1-enhancing agents","volume":"23","author":"Basova","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.lrr.2026.100586_bib0036","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/leu.2011.207","article-title":"CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors","volume":"26","author":"Negrotto","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.lrr.2026.100586_bib0037","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.exphem.2022.04.002","article-title":"Recurrent transcriptional responses in AML and MDS patients treated with decitabine","volume":"111","author":"Upadhyay","year":"2022","journal-title":"Exp. Hematol."},{"issue":"2","key":"10.1016\/j.lrr.2026.100586_bib0038","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3324\/haematol.2009.010611","article-title":"5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome\u2013a systematic review and meta-analysis","volume":"95","author":"Gurion","year":"2010","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.lrr.2026.100586_bib0039","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3324\/haematol.2011.048231","article-title":"A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy","volume":"97","author":"Lubbert","year":"2012","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.lrr.2026.100586_bib0040","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.lrr.2026.100586_bib0041","doi-asserted-by":"crossref","first-page":"41498","DOI":"10.18632\/oncotarget.17241","article-title":"Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis","volume":"8","author":"He","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.lrr.2026.100586_bib0042","first-page":"339","article-title":"Treatment of high-risk myelodysplastic syndromes","volume":"110","author":"Kroger","year":"2025","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.lrr.2026.100586_bib0043","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13148-021-01002-y","article-title":"Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival","volume":"13","author":"Cabezon","year":"2021","journal-title":"Clin. Epigenetics"},{"issue":"1","key":"10.1016\/j.lrr.2026.100586_bib0044","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13148-019-0704-3","article-title":"Genomic and epigenomic predictors of response to guadecitabine in relapsed\/refractory acute myelogenous leukemia","volume":"11","author":"Chung","year":"2019","journal-title":"Clin. Epigenetics"},{"issue":"10","key":"10.1016\/j.lrr.2026.100586_bib0045","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1038\/s41375-021-01318-x","article-title":"Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin\/DNA damage mutations","volume":"35","author":"Simonetti","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.lrr.2026.100586_bib0046","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-025-06543-3","article-title":"Comparative efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia treatment: a meta-analysis of clinical trials and Real-World outcomes","author":"Sanz-Solas","year":"2025","journal-title":"Ann Hematol"},{"key":"10.1016\/j.lrr.2026.100586_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2024.107518","article-title":"Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS\/MPN","volume":"142","author":"Montalban-Bravo","year":"2024","journal-title":"Leuk. Res."},{"issue":"3","key":"10.1016\/j.lrr.2026.100586_bib0048","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.lrr.2026.100586_bib0049","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.173646","article-title":"Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia","volume":"9","author":"Elgamal","year":"2024","journal-title":"JCI Insight"}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048926000269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048926000269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:11:41Z","timestamp":1785481901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048926000269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":49,"alternative-id":["S2213048926000269"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2026.100586","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting nucleotide metabolism and epigenetic regulation to overcome the differentiation blockade in AML","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2026.100586","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100586"}}